Is Pieris Pharmaceuticals Inc. (PIRS) Price Targeted To Increase?

At the last check on Thursday, Pieris Pharmaceuticals Inc.’s (NASDAQ:PIRS) stock was up $0.11, moving up 6.04 percent to $1.93. The average number of shares traded per day over the past five days has been 226,395 shares. 5 times new highs have been achieved over the past 5 days, with a $0.2450 gain in that time frame. In the last twenty days, the average volume was 307,729, while in the previous 50 days, it was 418,836.

Since last month, PIRS stock rose 1.11%. Shares of the company fell to $1.5400 on 06/16/22, the lowest level in the past month. A 52-week high of $6.15 was reached on 01/04/22 after having rallying from a 52-week low of $1.54. Since the beginning of this year, PIRS’s stock price has dropped by -51.85% or -$1.8850, and marked a new high 2 times. However, the stock has declined by -68.62% since its 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Pieris Pharmaceuticals Inc. (PIRS) last reported insider trading activity 41 days ago on May 13. Demuth Tim, the Chief Medical Officer of the company, purchased of 6,000 shares for $1.71 on May 13. It resulted in a $10,260 investment by the insider. Olwill Shane sold 38,400 shares at an average price of $5.11 on Aug 30. The insider now owns 4,638 shares following the transaction.

Valuation Metrics

The stock’s beta is 1.20. Besides these, the trailing price-to-sales (P/S) ratio of 4.76, the price-to-book (PB) ratio of 2.49.

Financial Health

In the three months ended March 30, Pieris Pharmaceuticals Inc.’s quick ratio stood at 2.80, while its current ratio was 2.80, showing that the company is able to pay off its debt. Based on annual data, PIRS earned $83.25 million in gross profit and brought in $31.42 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -94.80%. Return on equity (ROE) for the past 12 months was -91.20%.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. PIRS’s revenue rose 82.89% to $4.06 million during the quarter, while net income inched up to $10.99 million. While analysts expected Pieris Pharmaceuticals Inc. to report -$0.11 quarterly earnings, the actual figure was -$0.07 per share, beating the consensus estimate by 36.40%. During the quarter, the company generated -$6.61 million in EBITDA. The liabilities of Pieris Pharmaceuticals Inc. were 83.67 million at the end of its most recent quarter ended March 30, and its total debt was $14.89 million. The value of shareholders’ equity is $74.1 million.

Technical Picture

This quick technical analysis looks at Pieris Pharmaceuticals Inc.’s (PIRS) price momentum. With a historical volatility rate of 68.30%, the RSI 9-day stood at 61.75% on 22 June.

With respect to its five-day moving average, the current Pieris Pharmaceuticals Inc. price is up by +14.85% percent or $0.2450. At present, PIRS shares trade +14.16% above its 20-day simple moving average and -43.93% percent below its 100-day simple moving average. However, the stock is currently trading approximately -39.07% below its SMA50 and -63.56% below its SMA200.

Stochastic coefficient K was 72.58% and Stochastic coefficient D was 55.12%, while ATR was 0.1216. Given the Stochastic reading of 93.42% for the 14-day period, the RSI (14) reading has been calculated as 51.80%. As of today, the MACD Oscillator reading stands at 0.0989, while the 14-day reading stands at 0.0599.

Analyst Ratings

Robert W. Baird upgraded its rating on Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) to an Outperform in a note to investors on March 13, 2020. The analysts firm previously had a Neutral rating on the stock.Pieris Pharmaceuticals Inc. (PIRS) has been rated Buy by analysts. According to 0 brokerage firms, PIRS is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Pieris Pharmaceuticals Inc. stock as buy, with 2 recommending it as overweight.

With a median target price of $8.00, the current consensus forecast for the stock is $8.00 – $8.00. Based on these forecasts, analysts predict Pieris Pharmaceuticals Inc. (PIRS) will achieve an average price target of $8.00.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam